Cargando…

Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience

Breast cancer is a multifaceted disease that currently represents a leading cause of death in women worldwide. Over the past two decades (1998–2020), the National Health Laboratory Service’s Human Genetics Laboratory in central South Africa screened more than 2,974 breast and/or ovarian cancer patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Van der Merwe, Nerina C., Combrink, Herkulaas MvE, Ntaita, Kholiwe S., Oosthuizen, Jaco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024354/
https://www.ncbi.nlm.nih.gov/pubmed/35464868
http://dx.doi.org/10.3389/fgene.2022.834265
_version_ 1784690563282370560
author Van der Merwe, Nerina C.
Combrink, Herkulaas MvE
Ntaita, Kholiwe S.
Oosthuizen, Jaco
author_facet Van der Merwe, Nerina C.
Combrink, Herkulaas MvE
Ntaita, Kholiwe S.
Oosthuizen, Jaco
author_sort Van der Merwe, Nerina C.
collection PubMed
description Breast cancer is a multifaceted disease that currently represents a leading cause of death in women worldwide. Over the past two decades (1998–2020), the National Health Laboratory Service’s Human Genetics Laboratory in central South Africa screened more than 2,974 breast and/or ovarian cancer patients for abnormalities characteristic of the widely known familial breast cancer genes, Breast Cancer gene 1 (BRCA1) and Breast Cancer gene 2 (BRCA2). Patients were stratified according to the presence of family history, age at onset, stage of the disease, ethnicity and mutation status relative to BRCA1/2. Collectively, 481 actionable (likely-to pathogenic) variants were detected in this cohort among the different ethnic/racial groups. A combination of old (pre-2014) and new (post-2014) laboratory techniques was used to identify these variants. Additionally, targeted genotyping was performed as translational research revealed the first three recurrent South African pathogenic variants, namely BRCA1 c.1374del (legacy name 1493delC), BRCA1 c.2641G>T (legacy name E881X) and BRCA2 c.7934del (legacy name 8162delG). This initial flagship study resulted in a cost-effective diagnostic test that enabled screening of a particular ethnic group for these variants. Since then, various non-Afrikaner frequent variants were identified that were proven to represent recurrent variants. These include BRCA2 c.5771_5774del (legacy name 5999del4) and BRCA2 c.582G>A, both Black African founder mutations. By performing innovative translational research, medical science in South Africa can adopt first-world technologies into its healthcare context as a developing country. Over the past two decades, the progress made in the public sector enabled a pivotal shift away from population-directed genetic testing to the screening of potentially all breast and ovarian cancer patients, irrespective of ethnicity, family history or immunohistochemical status. The modifications over the years complied with international standards and guidelines aimed at universal healthcare for all. This article shares all the cohort stratifications and the likely-to pathogenic variants detected.
format Online
Article
Text
id pubmed-9024354
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90243542022-04-23 Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience Van der Merwe, Nerina C. Combrink, Herkulaas MvE Ntaita, Kholiwe S. Oosthuizen, Jaco Front Genet Genetics Breast cancer is a multifaceted disease that currently represents a leading cause of death in women worldwide. Over the past two decades (1998–2020), the National Health Laboratory Service’s Human Genetics Laboratory in central South Africa screened more than 2,974 breast and/or ovarian cancer patients for abnormalities characteristic of the widely known familial breast cancer genes, Breast Cancer gene 1 (BRCA1) and Breast Cancer gene 2 (BRCA2). Patients were stratified according to the presence of family history, age at onset, stage of the disease, ethnicity and mutation status relative to BRCA1/2. Collectively, 481 actionable (likely-to pathogenic) variants were detected in this cohort among the different ethnic/racial groups. A combination of old (pre-2014) and new (post-2014) laboratory techniques was used to identify these variants. Additionally, targeted genotyping was performed as translational research revealed the first three recurrent South African pathogenic variants, namely BRCA1 c.1374del (legacy name 1493delC), BRCA1 c.2641G>T (legacy name E881X) and BRCA2 c.7934del (legacy name 8162delG). This initial flagship study resulted in a cost-effective diagnostic test that enabled screening of a particular ethnic group for these variants. Since then, various non-Afrikaner frequent variants were identified that were proven to represent recurrent variants. These include BRCA2 c.5771_5774del (legacy name 5999del4) and BRCA2 c.582G>A, both Black African founder mutations. By performing innovative translational research, medical science in South Africa can adopt first-world technologies into its healthcare context as a developing country. Over the past two decades, the progress made in the public sector enabled a pivotal shift away from population-directed genetic testing to the screening of potentially all breast and ovarian cancer patients, irrespective of ethnicity, family history or immunohistochemical status. The modifications over the years complied with international standards and guidelines aimed at universal healthcare for all. This article shares all the cohort stratifications and the likely-to pathogenic variants detected. Frontiers Media S.A. 2022-04-08 /pmc/articles/PMC9024354/ /pubmed/35464868 http://dx.doi.org/10.3389/fgene.2022.834265 Text en Copyright © 2022 Van der Merwe, Combrink, Ntaita and Oosthuizen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Van der Merwe, Nerina C.
Combrink, Herkulaas MvE
Ntaita, Kholiwe S.
Oosthuizen, Jaco
Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience
title Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience
title_full Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience
title_fullStr Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience
title_full_unstemmed Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience
title_short Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience
title_sort prevalence of clinically relevant germline brca variants in a large unselected south african breast and ovarian cancer cohort: a public sector experience
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024354/
https://www.ncbi.nlm.nih.gov/pubmed/35464868
http://dx.doi.org/10.3389/fgene.2022.834265
work_keys_str_mv AT vandermerwenerinac prevalenceofclinicallyrelevantgermlinebrcavariantsinalargeunselectedsouthafricanbreastandovariancancercohortapublicsectorexperience
AT combrinkherkulaasmve prevalenceofclinicallyrelevantgermlinebrcavariantsinalargeunselectedsouthafricanbreastandovariancancercohortapublicsectorexperience
AT ntaitakholiwes prevalenceofclinicallyrelevantgermlinebrcavariantsinalargeunselectedsouthafricanbreastandovariancancercohortapublicsectorexperience
AT oosthuizenjaco prevalenceofclinicallyrelevantgermlinebrcavariantsinalargeunselectedsouthafricanbreastandovariancancercohortapublicsectorexperience